ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cardiovascular disease"

  • Abstract Number: 1565 • 2018 ACR/ARHP Annual Meeting

    Comorbidity Burden in Primary Sjögren’s Syndrome: A Long-Term Observation in Clinical Practice

    Chiara Baldini1, Francesco Ferro1, Nicoletta Luciano1, Emanuele Calabresi1, Antonella Cecchettini2, Marta Mosca1, Enzo Grossi1 and Stefano Bombardieri1, 1Rheumatology Unit, University of Pisa, Pisa, Italy, 2IFC, CNR, Pisa, Italy

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is a complex disorder that may affect any organ and system. In this new era of personalized medicine, a growing…
  • Abstract Number: 1913 • 2018 ACR/ARHP Annual Meeting

    Management of Ventricular Tachycardia and Cardiomyopathy in the Rheumatologist World: A Retrospective Review of Diagnostic Tools and Treatment Decisions for Cardiac Sarcoidosis

    Saba Ziaee1, Siri Kunchakarra2, Cara Joyce3, Mark Rabbat4 and Rochella A. Ostrowski5, 1Loyola University Medical Center, Maywood, IL, 2Cardiology, Loyola University Medical Center, Maywood, IL, 3Clinical Research Office, Loyola University Medical Center, Maywood, IL, 4Division of Cardiology, Loyola University Medical Center, Maywood, IL, 5Division of Rheumatology, Loyola University Medical Center, Maywood, IL

    Background/Purpose: Cardiac sarcoidosis has been noted in 2-7% of patients with sarcoidosis.  However, the incidence is >20% based on necropsy data.  Given the poor yield…
  • Abstract Number: 2817 • 2018 ACR/ARHP Annual Meeting

    Cardiovascular Disease Risk with Biologics and Tofacitinib Compared to Conventional Synthetic Dmards in Patients with Rheumatoid Arthritis

    Gulsen Ozen1, Sofia Pedro2 and Kaleb Michaud1,2, 1Rheumatology, University of Nebraska Medical Center, Omaha, NE, 2FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS

    Background/Purpose: Cardiovascular disease (CVD) represents the leading cause of death in RA, accounting for ~50% of excess mortality. Disease activity, strongly linked to CVD, has…
  • Abstract Number: 507 • 2018 ACR/ARHP Annual Meeting

    Echocardiographic Markers of Right Ventricle Dysfunction in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study

    José R. Azpiri-López1, Dionicio A. Galarza-Delgado2, Iris J. Colunga-Pedraza3, Jose A. Davila-Jimenez4, Estefania E. Abundis-Marquez4, Andres H. Guillen-Lozoya4, Francisco J. Torres-Quintanilla4, Aldo Valdovinos-Bañuelos4, Ray Ramos-Cázares4, Raymundo Vera-Pineda4, Jesus A. Cardenas-de la Garza4, Rosa I. Arvizu-Rivera4 and Adrián Martínez-Moreno4, 1Cardiology, Hospital Universitario, UANL, Monterrey, Mexico, 2Chief of Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, 3Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, 4Hospital Universitario, UANL, Monterrey, Mexico

    Background/Purpose: Screening for cardiovascular (CV) disease in patients with rheumatoid arthritis (RA) remains controversial, however, there is agreement in considering echocardiography as the most immediate…
  • Abstract Number: 812 • 2018 ACR/ARHP Annual Meeting

    Inflammatory Stays Inflammatory: A Subgroup of Systemic Sclerosis Characterized By High Morbidity and Inflammatory Resistance to Cyclophosphamide

    Aleksey Mitev1, Daria Feldmann1, Moritz Binder2, Kim Möller3, Anna-Maria Kanne1, Thomas Hügle4, Peter M. Villiger5, Reinhard Voll6, Stephanie Finzel1 and Florian Kollert7, 1Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 2Department of Internal Medicine, Mayo Clinic, Rochester, MN, 3Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 4Rheumatology, University Hospital Lausanne (CHUV), Lausanne, Switzerland, 5Rheumatology and Clin Immunol, Bern, Switzerland, 6Clinic for Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 7Department of Rheumatology, Immunology, and Allergology, Inselspital, University Hospital Bern, Bern, Switzerland

    Background/Purpose: Elevated levels of C-reactive protein (CRP) in systemic sclerosis (SSc) have been linked to early inflammatory stages of the disease. This study has been…
  • Abstract Number: 1589 • 2018 ACR/ARHP Annual Meeting

    Cardiac Biomarkers and Carotid Atherosclerosis and Its Progression in Psoriatic Disease

    Lihi Eder1, Vinod Chandran2, Iain B. McInnes3, Richard J. Cook4, Dafna D Gladman5, Paul Welsh6, Naveed Sattar7 and Paula Harvey8, 1Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, 2Krembil Research Institute & University of Toronto, Toronto, ON, Canada, 3University of Glasgow, Glasgow, United Kingdom, 4Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 5Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 6nstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, 7Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, 8Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Laboratory biomarkers indicative of cardiac ischemia or dysfunction improve cardiovascular (CV) risk stratification in the general population. Their utility in patients with psoriatic disease…
  • Abstract Number: 2030 • 2018 ACR/ARHP Annual Meeting

    Patients with Childhood-Onset SLE (cSLE) and Hypertension Have Consistently Higher Serum Concentrations of C3 and C4 Than Those without Hypertension

    Evan Mulvihill1, Stacy P. Ardoin2, Susan D Thompson3, Bi Zhou4, Gakit Yu5, Nora G. Singer6, Deborah M. Levy7, Hermine I. Brunner8, Yee Ling Wu9, Haikady Nagaraja10, Laura E. Schanberg11 and Chack-Yung Yu2, 1Pediatrics and Rheumatology, Nationwide Children's Hospital, Columbus, OH, 2Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, 3Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, 5Center for Molecular and Human Genetics, Nationwide Children's Hospital, Columbus, OH, 6Departments of Medicine and Pediatrics, Division of Rheumatology, MetroHealth Medical Center, Cleveland, OH, Cleveland, OH, 7Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, 8Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 9Department of Microbiology and Immunology, Loyola University Chicago, Chicago, IL, 10College of Public Health, The Ohio State University, Columbus, OH, 11Duke University Medical Center, Durham, NC

    Background/Purpose: Chronic systemic inflammation, mediated in part by complement, and inadequate vascular repair mechanisms affect patients with cSLE from a young age and are associated…
  • Abstract Number: 2818 • 2018 ACR/ARHP Annual Meeting

    Galectin-3 As a Marker of Subclinical Atherosclerosis, Arterial Stiffness and Myocardial Performance in Patients with Rheumatoid Arthritis

    Panagiota Anyfanti1, Eugenia Gkaliagkousi1, Areti Triantafyllou1, Eleni Gavriilaki1, Panagiotis Dolgyras1, Sophia Chatzimichailidou2, Vasiliki Galanopoulou3, Stella Douma1 and Spyros Aslanidis2, 13rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, 2Rheumatology Department-2nd Propedeutic Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, 3Rheumatology Department, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece

    Background/Purpose: Galectin-3 has emerged as a promising novel biomarker of cardiovascular fibrosis, that can improve cardiovascular risk stratification in high-risk populations. Rheumatoid arthritis (RA) is…
  • Abstract Number: 508 • 2018 ACR/ARHP Annual Meeting

    Non-Invasive Evaluation of Left Atrial Pressure in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study

    José R. Azpiri-López1, Dionicio A. Galarza-Delgado2, Iris J. Colunga-Pedraza3, Jose A. Davila-Jimenez4, Estefania E. Abundis-Marquez4, Andres H. Guillen-Lozoya4, Francisco J. Torres-Quintanilla4, Aldo Valdovinos-Bañuelos4, Ray Ramos-Cázares4, Raymundo Vera-Pineda4, Jesus A. Cardenas-de la Garza4, Rosa I. Arvizu-Rivera4 and Adrián Martínez-Moreno4, 1Cardiology, Hospital Universitario, UANL, Monterrey, Mexico, 2Chief of Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, 3Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, 4Hospital Universitario, UANL, Monterrey, Mexico

    Background/Purpose: In the last several years a higher prevalence of heart failure has been described in Rheumatoid arthritis (RA) patients, particularly heart failure with preserved…
  • Abstract Number: 856 • 2018 ACR/ARHP Annual Meeting

    Integrated mRNA and microRNA Transcriptomes of Monocytes from Antiphospholipid Syndrome Patients Identifies Molecular Networks Related to Their Atherothrombotic Status. Modulatory Effects of In Vivo Ubiquinol Supplementation

    Carlos Perez-Sanchez1, Laura Pérez Sánchez2, Alejandra Maria Patiño-Trives3, María Luque Tevar3, Luca Scudeler4, Alejandro Ibáñez-Costa3, Patricia Ruiz-Limon5, Yolanda Jiménez-Gómez1, Ivan Arias de la Rosa6, Maria Carmen Abalos-Aguilera6, Pedro Segui7, Nuria Barbarroja1, Jose Manuel Villalba8, Eduardo Collantes Estevez3, Maria Jose Cuadrado9, Maria Ángeles Aguirre Zamorano1 and Chary Lopez-Pedrera3, 1Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 2IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 3IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 4Università degli Studi di Torino, Turin, Italy, 5Research Group of Endocrine Diseases, Research Laboratory. Biomedical Research Institute of Malaga (IBIMA).Virgen de la Victoria Universitary Hospital, Malaga, Spain., Málaga, MA, Spain, 6Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 7Radiology, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 8Departamento de Biologia Celular, Fisiologia e Inmunología, University of Córdoba, Cordoba, Spain, 9Clinica Universidad de Navarra, Madrid, Spain

    Background/Purpose: 1. To characterize the mRNAs and microRNAs transcriptomes of monocytes, key immune cells in the atherothrombotic pathology of Antiphospholipid Syndrome patients (APS). 2. To…
  • Abstract Number: 1590 • 2018 ACR/ARHP Annual Meeting

    Metabolomics Profile Predicts Carotid Atherosclerosis Progression in Psoriatic Disease

    Lihi Eder1, Paula Harvey2, Paul Welsh3, Vinod Chandran4, Iain B. McInnes5, Richard J. Cook6, Dafna D Gladman7 and Naveed Sattar8, 1Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, 2Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, 3nstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, 4Krembil Research Institute & University of Toronto, Toronto, ON, Canada, 5University of Glasgow, Glasgow, United Kingdom, 6Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 7Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 8Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Metabolomic profiling of patients with psoriatic disease (PsD) offers unparalleled opportunity to unravel the molecular and clinical interactions linking PsD with cardiovascular (CV) risk.…
  • Abstract Number: 2075 • 2018 ACR/ARHP Annual Meeting

    Vascular Endothelial and Inflammatory Differences in Psoriasis and Psoriatic Arthritis Patients

    Michael Gashick1, Todd Wechter2, Tessa Barrett1, Sarah Azarchi2, Stuart Katz3, Andrea L. Neimann4, James Krueger5, Sanja Jelic6, Edward Fisher1, Jose U. Scher7 and Jeffrey S. Berger8, 1Medicine/Cardiology, New York University School of Medicine, New York City, NY, 2Dermatology, New York University School of Medicine, New York City, NY, 3Medicine/Cardiology, New York University School of Medicine, New York, NY, 4Department of Dermatology, New York University School of Medicine, New York, NY, 5The Rockefeller University, New York, NY, 6Medicine/Pulmonary, Columbia University Medical Center, New York City, NY, 7New York University School of Medicine, New York, NY, 8Medicine, Division of Cardiology, New York University School of Medicine, New York, NY

    Background/Purpose: Psoriatic arthritis (PsA) and Psoriasis (PsO) are chronic inflammatory diseases associated with vascular inflammation and increased CVD risk. Few studies have examined vascular inflammatory…
  • Abstract Number: 2847 • 2018 ACR/ARHP Annual Meeting

    Associations between Serum Uric Acid Level and Coronary Artery Disease

    Patricia Kachur1,2, Satish Tadepalli3, Sergey Kachur4 and Pramil Cheriyath3, 1Rheumatolgy, Ochsner Foundation Hospital, New Orleans, LA, 2Internal Medicine, Ocala Regional Medical Center, Ocala, FL, 3Hackensack Meridian Health, Ocean Medical Center, Brick, NJ, 4Ocala Regional Medical Center, Ocala, FL

    Title: Association between Serum Uric Acid Level and Coronary Artery DiseaseBackground/Purpose: Previous studies have shown an unclear relationship between serum uric acid (SUA) and coronary…
  • Abstract Number: 509 • 2018 ACR/ARHP Annual Meeting

    Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the Ontario Best Practices Research Initiative

    Kathy Cui1, Mohammad Movahedi2, Claire Bombardier3 and Bindee Kuriya4,5,6, 1Western University, London Health Sciences Centre, London, ON, Canada, 2JSS Medical Research, St-Laurent, QC, Canada, 3Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 4Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5Sinai Health System, University of Toronto, Toronto, ON, Canada, 6Rheumatology, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Rheumatoid arthritis increases the risk of cardiovascular disease (CVD). Less is known about the direct influence of CVD on RA outcomes, but higher comorbidity…
  • Abstract Number: 863 • 2018 ACR/ARHP Annual Meeting

    Combining Cardiac Magnetic Resonance and Right Heart Catheterization to Evaluate Right Ventricular Function for the Prognosis Prediction in Patients with Connective Tissue Diseases and Pulmonary Hypertension

    Nobuya Abe1, Masaru Kato2, Hiroyuki Nakamura2, Atsushi Noguchi2, Yuichiro Fujieda2, Kenji Oku2, Toshiyuki Bohgaki2, Olga Amengual2, Shinsuke Yasuda2 and Tatsuya Atsumi2, 1Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 2Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

    Background/Purpose: Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH), particularly PAH associated with systemic sclerosis (SSc-PAH), has a poor prognosis compared with other PAH.…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology